ImmunityBio, Inc. IBRX

ImmunityBio, Inc. (IBRX) shares jumped about 9.9% after founder Dr. Patrick Soon-Shiong met Turkish President Recep Tayyip Erdogan, fueling optimism around expanding the company’s activities in Turkey. The Turkish government shared a photo of the meeting, which Soon-Shiong reposted with the note that Turkey could become a cancer-care hub in the region. While details were not disclosed, analysts and investors see progress on ImmunityBio’s plan to expand into Turkey as part of its broader push into 34 countries for its Anktiva immunotherapy. The company recently raised $100 million in new funding—$75 million as non-dilutive financing from Oberland Capital and $25 million via a Nant Capital LLC debt-to-share conversion. In Q2, Anktiva revenue helped total revenues reach $51.24 million (up 94% YoY), but net loss widened to $230.4 million due to higher costs. Hedge funds joined the bullish view with rising positions. High-profile international engagement and new funding could materially shift growth expectations and investor sentiment.

ImmunityBio (IBRX) shares rose after founder Patrick Soon-Shiong teased Nant's plan to launch blockchain-based stock trading and tokenized U.S. equities. The SEC's Innovation Exemption creates a five-year path for venues to trade tokenized stocks, with token holders entitled to the same dividends, voting and proxy rights. Nant Global Finance is building broker-dealer, transfer-agent, exchange and blockchain-settlement capabilities through acquisitions of Horizon Globex, BlockAgent and Equity Stock Transfer, plus stakes in TradingBlock, Digital Offering and Arkonis Capital. Soon-Shiong, ImmunityBio's executive chairman, owns about 65.5% of IBRX via Nant-related entities. Retail chatter on StockTwits turned bullish, betting tokenization could arrive within weeks and reduce phantom shares or shorts’ pressure. Questions remain whether PDS Biotech could join the platform. IBRX has jumped year-to-date. Tokenization remains speculative and contingent on regulatory approval and platform execution, implying a moderate potential impact.

Nant Capital backs ImmunityBio's second cancer-immunotherapy project, driving gains in IBRX stock. Nant Capital investment advances ImmunityBio cancer immunotherapy pipeline and lifts stock.

IBRX and SLS stocks attract investor attention ahead of major cancer conferences and new drug data releases. Major cancer conferences and new drug data releases for IBRX signal potential significant shifts in market sentiment and company trajectory.

IBRX stock heads for its worst week since July as a new patent expands Anktiva use ahead of a lung cancer conference. New patent broadens Anktiva applications and may shift company trajectory and investor views ahead of key conference.

Manulife’s unit increases its stake in ImmunityBio (IBRX) and SLS ahead of key cancer catalysts. Manulife unit stake increase signals added investor interest in IBRX before cancer catalysts.

IBRX stock heads for best week in over 2 months after update on Chairman Soon Shiong’s cancer vaccine trial milestone. Cancer vaccine trial milestone advances key pipeline with potential to alter long-term trajectory and sentiment.

Cathie Wood’s ARK backs personalized cancer vaccines, creating fresh oncology momentum for ImmunityBio (IBRX) and SLS. ARK endorsement signals major investor interest that can shift IBRX sentiment and trajectory in oncology.

Major US pension fund shows interest in IBRX and SLS. Significant clinical catalysts approach for ImmunityBio. Pension fund attention plus pending clinical catalysts can drive major shifts in IBRX trajectory and sentiment.

Goldman Sachs has built a $75 million investment across CAPR, SLS and IBRX ahead of major catalysts. Goldman Sachs stake signals institutional confidence that may lift near-term sentiment for IBRX.

ImmunityBio appoints Dr. Jim Yong Kim, former World Bank president and global health leader, as vice chairman. High-profile board addition brings global health expertise that may support strategic expansion and investor sentiment without altering core operations.

ImmunityBio (IBRX) secures broad UAE approval for ANKTIVA while ongoing losses threaten to alter the bull case. UAE regulatory approval expands ANKTIVA market access and could shift company trajectory amid persistent losses.

IBRX Q2 earnings and sales beat estimates on strong Anktiva uptake. Earnings beat driven by Anktiva demand points to revenue growth and improved commercial traction.

Pfizer, Merck and Amgen increase cancer investments, triggering takeover speculation around ImmunityBio (IBRX) and SLS. Takeover rumors tied to major pharma cancer moves can sharply lift IBRX valuation and trajectory.

ImmunityBio posts record Q2 sales for Anktiva while founder Soon-Shiong commits capital to the drug's next growth phase. Record quarterly sales plus founder capital commitment point to major revenue acceleration and pipeline momentum.

ImmunityBio reported record Q2 2026 net product revenue of $50.7 million, up 92% year-over-year. First-half revenue rose 121% to $94.8 million. Record revenue growth with high double-digit increases signals major positive shift in financial trajectory and investor outlook.

UAE approves ANKTIVA for bladder and lung cancer treatments, driving gains for ImmunityBio, Inc. UAE approval of ANKTIVA opens new markets for core products and lifts company performance.

UAE grants broadest approval yet for Anktiva. IBRX stock jumps overnight after founder's July birthday news tease. UAE approval of Anktiva delivers major regulatory win that expands market access and lifts stock.

ImmunityBio secures UAE marketing authorization for ANKTIVA in BCG-unresponsive non-muscle invasive bladder cancer for CIS and papillary disease plus metastatic non-small cell lung cancer. UAE approval expands ANKTIVA market access and revenue potential across two cancer indications.

IBRX stock falls for a fifth straight day as retail traders await robust Anktiva sales and an earnings beat. Upcoming Anktiva sales figures and earnings results may moderately shift IBRX financial performance and sentiment.

Analysis finds ImmunityBio (IBRX) shares potentially 41% undervalued driven by optimism over Anktiva. Positive valuation view tied to Anktiva raises near-term investor attention without altering core operations.

IBRX stock climbs in premarket trading despite an investor cutting stake, as retail investors anticipate an imminent global rollout catalyst. Potential global rollout expectations may moderately affect ImmunityBio market sentiment and trajectory.

IBRX stock hits 3-month high as retail investors target July catalysts tied to Anktiva Saudi expansion and Q2 sales results. Anktiva Saudi expansion and Q2 sales data may lift near-term sentiment and operations but are unlikely to alter long-term trajectory.

ImmunityBio (IBRX) and SLS anticipate positive momentum this month amid rising biotech ETF performance, as analysts highlight continued opportunities in immuno-oncology. Analyst optimism on immuno-oncology prospects supports moderate positive effects on IBRX market trajectory.

ImmunityBio presented ASCO data on ANKTIVA demonstrating efficacy in lung and bladder cancer, reframing treatment outlooks and boosting company prospects. Positive ASCO clinical data on ANKTIVA for lung and bladder cancer signals major strategic and market impact.

ImmunityBio presented new clinical and comparative data across lung and bladder cancer at ASCO 2026. Conference data presentation on core oncology pipeline may lift visibility and short-term sentiment without guaranteed fundamental shifts.

ImmunityBio reported Q1 results and faces a new FDA review, shaping near-term stock outlook. Q1 results plus new FDA review can materially shift regulatory path and investor views on IBRX.

ImmunityBio's Anktiva secures FDA approval for BCG-unresponsive non-muscle invasive bladder cancer, detailing its IL-15 superagonist mechanism and outlining next steps including label expansions, commercialization ramp-up, and additional pipeline indications. Anktiva approval and commercialization details signal major revenue potential and pipeline momentum that can materially shift ImmunityBio's trajectory.

Health economic analysis positions ImmunityBio ANKTIVA as offering superior value over TAR-200. Positive health economic comparison to competitor product may lift near-term sentiment and positioning in bladder cancer market.

ImmunityBio seeks ANKTIVA label expansion into papillary NMIBC, a move positioned as potentially transformative for the company's market position and growth trajectory. Label expansion bid for ANKTIVA in papillary NMIBC represents a potential game-changing regulatory and commercial development for ImmunityBio.